← Back
Unitedhealth Group
UNH · listed on the New York Stock Exchange · worth $368.83 billion
$410.91
+0.94% on Oct 29
No insider bought Unitedhealth Group stock in the last year. They sold it 2 times, $660.9K in all. Twelve members of Congress reported trading Unitedhealth Group in the last year.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
899.4M shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider sold Unitedhealth Group stock and none bought. None of the 2 sales is marked on its filing as planned in advance; all by company executives.
Planned sales
Form 144 notices filed for Unitedhealth Group in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
CEO Patrick Hugh Conway filed to sell 1,169 shares on 21 Aug; sold 1,169 by 21 AugNotice on SEC.gov
CEO Patrick Hugh Conway filed to sell 500 shares on 5 Aug; sold 500 by 5 AugNotice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Unitedhealth Group, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.State Street5.0%Aug 7
US Congress
Members of Congress who reported trading Unitedhealth Group in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Unitedhealth Group.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 25SoldPatrick Hugh ConwayAug 25 · Traded Aug 21 · Chief Executive Officer, Optum1,169 @ $390.00$455.9K
Sep 15, 2025SoldCharles D. BakerSep 15, 2025 · Traded Sep 11, 2025 · Directorvia a trust or family27 @ $356.05$9.6K
Jun 12, 2025SoldPatrick Hugh ConwayJun 12, 2025 · Traded Jun 10, 2025 · Chief Executive Officer, Optum589 @ $305.00$179.6K
Analysts, earnings and news
Analysts' price target
$411.88 average
26 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q1 '26$7.23 a share+$0.63
Q4 '25$2.11 a share+$0.00
Q3 '25$2.92 a share+$0.11
Q2 '25$4.08 a share−$0.37